A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.
Cannabis Use Disorder Clinical Trial Pipeline Gains Momentum
The federal executive order on cannabis rescheduling does NOT make recreational marijuana legal—it eases research restrictions and tax burdens, but full legalization still requires an act of Congress. OpenPR reports that the clinical trial pipeline for cannabis use disorder (CUD) treatments is gaining momentum, with pharmaceutical R&D intensifying focus on targeted therapies. Aelis Farma is advancing AEF0117, a selective CB1 modulator, through Phase II trials.